Mesoblast (MEOBF) Net Cash Flow Growth (1y) (2015 - 2023)
Powered by 
Analysis
Mesoblast (MEOBF) Net Cash Flow Growth (1y) (2015 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | -263.05% |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | -111.96% |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 114.92% |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -61.56% |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 1,842.32% |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 1,022.41% |
| Mar 31, 2023 | -343.42% |
| Dec 31, 2022 | 168.02% |
| Sep 30, 2022 | 240.95% |
| Jun 30, 2022 | 24.43% |
| Mar 31, 2022 | -122.35% |
| Dec 31, 2021 | 33.25% |
| Sep 30, 2021 | 173.48% |
| Mar 31, 2021 | 714.35% |
| Dec 31, 2020 | -203.72% |
| Sep 30, 2020 | -36.97% |
| Mar 31, 2020 | 248.53% |
| Dec 31, 2019 | -44.65% |
| Sep 30, 2019 | -190.44% |
| Mar 31, 2019 | -155.51% |
| Dec 31, 2018 | 458.05% |
| Sep 30, 2018 | 0.33% |
| Jun 30, 2018 | 7.24% |
| Mar 31, 2018 | -65.27% |
| Dec 31, 2017 | 39.56% |